In this time of dire need, Sepragen team is doing its part to solve the problem of COVID-19. We are providing equipment on an expedited basis to a company developing a vaccine for COVID- 19.
Sepragen wins NIIMBL grant

Sepragen wins NIIMBL grant

Sepragen along with SUNY, Albany win NIIMBL grant for “Novel Bioreactor for hematopoietic cell expansion.

news
You may also like
Browse All
January 2021
Sepragen wins NIIMBL award
In the creation of bio-pharmaceutical drugs, cells are genetically modified to produce some compound shown by research to have a desired effect in a treatment program.
Learn more
September 2020
Sepragen ships Custom Chromatography Systems
Sepragen’s products or tools are used to manufacture over 24 FDA approved drugs including Kogenate®, Alphanate®, Neupogen®, and GammaGrand®* along with a multitude...
Learn more
September 2019
Sepragen partners with I&L Biosystems
Sepragen has pioneered the three patented processes for the isolation of high value nutritionals on a commercial scale. The Sepralac® Process enables the isolation of Lactoferrin...
Learn more